KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Acquisitions (2016 - 2025)

AbbVie (ABBV) has disclosed Acquisitions for 10 consecutive years, with $204.0 million as the latest value for Q1 2025.

  • On a quarterly basis, Acquisitions fell 97.78% to $204.0 million in Q1 2025 year-over-year; TTM through Dec 2025 was $204.0 million, a 98.83% decrease, with the full-year FY2025 number at $204.0 million, down 98.83% from a year prior.
  • Acquisitions was $204.0 million for Q1 2025 at AbbVie, down from $8.3 billion in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $9.2 billion in Q1 2024 to a low of $204.0 million in Q1 2025.
  • A 3-year average of $4.6 billion and a median of $4.4 billion in 2021 define the central range for Acquisitions.
  • Peak YoY movement for Acquisitions: surged 330.33% in 2021, then tumbled 97.78% in 2025.
  • AbbVie's Acquisitions stood at $525.0 million in 2021, then soared by 1479.81% to $8.3 billion in 2024, then crashed by 97.54% to $204.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Acquisitions are $204.0 million (Q1 2025), $8.3 billion (Q3 2024), and $9.2 billion (Q1 2024).